Peer-reviewed veterinary case report
Combining oclacitinib and lokivetmab helps dogs when one alone fails
By Bachtel, Jeremy C & Snidow, McKenna·Published in Veterinary dermatology·2026·Veterinary Referral Center of Colorado, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Efficacy of Combination Oclacitinib and Lokivetmab Therapies After Monotherapeutic Failure in 44 Dogs: A Retrospective Study.
- Species:
- dog
Plain-English summary
A group of 44 dogs with allergic dermatitis that didn't improve with either oclacitinib or lokivetmab were treated with a combination therapy of both medications. After starting this combination treatment, 27 of the dogs showed significant improvement, with their itching scores dropping from an average of 6.87 to 2.67 out of 10. This means that more than half of the dogs experienced relief from their symptoms without any side effects. The combination therapy appears to be a promising option for dogs that haven't responded to standard treatments.
People also search for: dog itching treatment · allergic dermatitis in dogs · oclacitinib and lokivetmab for dogs
Abstract
BACKGROUND: Oclacitinib and lokivetmab are generally effective monotherapies for the treatment of canine allergic dermatitis yet treatment failures may occur. OBJECTIVE: To evaluate the efficacy of the combination of oclacitinib-lokivetmab therapy (COLT) in dogs that previously failed monotherapy. ANIMALS: Forty-four client-owned dogs diagnosed with allergic dermatitis that did not respond to both oclacitinib and lokivetmab as monotherapies were then treated with COLT. RESULTS: Twenty-seven of 44 (61.4%) dogs responded adequately to COLT based on a ≥ 2 cm reduction in the pruritus Visual Analog Scale (pVAS) score from baseline and client/clinician consensus on improvement. In dogs that responded, the mean pVAS for monotherapy (oclacitinib and lokivetmab group data combined) was 6.87 of 10 and fell to 2.67 of 10 after COLT (61.1% decrease; p < 0.0001). No adverse effects were noted with COLT. CONCLUSIONS AND CLINICAL RELEVANCE: This study suggests that in dogs not adequately responsive to oclacitinib or lokivetmab monotherapy, COLT may provide superior control of pruritus.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/41189387/